AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$HIMS

Hims & Hers Stock Drops After It Cuts EBITDA Outlook

Hims & Hers Health (HIMS) reported Q3 revenue of $890.4M, up 49% but below estimates. It posted a loss of $0.14 per share, with gross margin falling to 57% and adjusted EBITDA margin narrowing to 9%. Subscribers grew 13% to 2.8M, and revenue per subscriber rose 30%.

Original reporting
finance.yahoo.com
Published Nov 10, 2026, 11:18 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 11:33 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Hims & Hers Stock Drops After It Cuts EBITDA Outlook — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$HIMSBearishHigh
01

Why it matters

The earnings miss and EBITDA outlook cut triggered a 3.4% pre‑market decline, indicating immediate downside risk.

02

Market read

The earnings release provides fresh, material information that can affect short‑term trading decisions on HIMS.

03

What to watch

Potential cost‑reduction initiatives and upcoming product launches that may improve margins in the next quarter.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Hims & Hers Health Inc. (NYSE:HIMS) is a telehealth and wellness platform that recently reported Q3 results.

Company-level read

Ticker impact

$HIMSBearishHigh confidence
Context

Hims & Hers reported Q3 results with revenue slightly below expectations and cut its EBITDA outlook, sending the stock down 3.4% pre‑market.

Expected impact

downward pressure as investors price in weaker guidance

Evidence & confidence

Revenue missed consensus and EBITDA margin narrowed; guidance cut signals lower future cash flow, prompting sell‑off.

Market effects

Sector

Telehealth sector may face broader scrutiny as earnings miss highlights margin pressure.

Regional

U.S. market sentiment could be slightly dampened by the downgrade in a high‑growth health tech name.

Global

Limited; impact confined to U.S. listed health‑tech stocks.

Counterpoint

What could challenge this read

If the revenue miss is viewed as a temporary hiccup and the subscriber base continues to grow, the stock could rebound on a short‑cover rally.

Key entities

  • company
    Hims & Hers Health Inc.

    U.S. listed telehealth provider reporting Q3 earnings.

Read at source← All news

StoryHims & Hers posts 49% revenue growth but margin collapse and cuts 2026 guidance

Also covered by

5 outlets

Related articles

$HIMSMed

HIMS May See Heightened ‘Gyrations’ As Weight-Loss Drug Trends Fuel Subscriber Uncertainty, Jefferies Warns – Stock Hits 7-Month Lows

Hims & Hers Health (HIMS) shares fell 15% after Q3 earnings missed expectations, with subscribers declining sequentially. Jefferies lowered its price target to $24, citing volatility from weight-loss drug trends. Needham reduced its target to $32 but kept a 'Buy' rating. The company reported a Q3 loss and cut its FY2026 EBITDA and revenue guidance.

finance.yahoo.com
$HIMSHighAI 8/10

Hims & Hers Stock Falls 15% on Weak Q4 Revenue Outlook

Hims & Hers Health (HIMS) shares dropped 15% after the company issued Q4 revenue guidance below expectations, forecasting $875M–$895M vs. analysts' $955.1M estimate. Q3 revenue grew 49% to $890.4M but gross margin declined to 57% from 74%. The company also faces regulatory challenges over weight-loss medications and data privacy.

grafa.com
$HIMSHighAI 8/10

Hims & Hers cuts 2026 earnings outlook despite 49% revenue growth

Hims & Hers Health (HIMS) reported 49% revenue growth in Q3, but lowered its 2026 adjusted EBITDA forecast to $257M-$277M. Revenue guidance was tightened to $3.13B-$3.15B, with Q4 sales expected at $875M-$895M. International revenue surged 321%, while gross margin contracted to 57% from 74%. The company reported a net loss of $33M, with adjusted EBITDA margin falling to 9% from 13%.

finance.yahoo.com